Several case reports have been published, and four trials have assessed the efficacy and safety of PD-1/PD-L1 inhibitors in patients with advanced thymic epithelial tumors (Table 3) [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58]]. The gene discussed is CD274; the disease is thymic epithelial neoplasm.